Medical Oncologist, Department of Medicine
Member of Faculty, Harvard Medical School
Attending Physician, Jerome Lipper Multiple
Myeloma Center
Dana-Farber Cancer Institute
Boston, MA
This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner. Read More ›
The ICARIA-MM and IKEMA-MM phase 3 trials have been pivotal in identifying Isa’s high efficacy and favorable tolerability profile as a notable therapy in the role of RRMM management. Recently, there have been additional updates illustrating the unique effects of Isa. This article focuses on these updates and how they may inform the role of Isa in the treatment of MM. Read More ›
